NT-proBNP、ET-1及CGRP水平与老年COPD合并肺心病NYHA心功能分级的相关性

doi:10.3969/j.issn.1671-7171.2023.07.018

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1191 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the correlation between severity of chronic obstructive pulmonary disease (COPD) complicated with pulmonary heart disease and levels of N-terminal B-type brain natriuretic peptide precursor (NT-proBNP), endothelin-1 (ET-1) and calcitonin gene-related peptide (CGRP) in elderly patients. 【Methods】A total of 108 elderly patients with COPD diagnosed and treated in the First People's Hospital of Xianyang City from January 2020 to January 2022 were selected in the study. According to whether the patients were complicated with pulmonary heart disease, they were divided into simple COPD group and COPD complicated with pulmonary heart disease group (combined group).Plasma levels of NT-proBNP, ET-1 and CGRP were detected in all patients. The value of plasma NT-proBNP, ET-1 and CGRP in the diagnosis of COPD complicated with pulmonary heart disease was analyzed by receiver operating characteristic (ROC) curve. Spearman correlation coefficient was used to analyze the correlation of plasma levels of NT-proBNP, ET-1 and CGRP with cardiac function classification of New York Heart Association (NYHA) in elderly COPD patients with pulmonary heart disease. 【Results】Compared with the simple COPD group, the levels of NT-proBNP and ET-1 were higher, while the level of CGRP weas lower in COPD group combined with pulmonary heart disease (P<0.05).ROC analysis showed that the best cutoff values of NT-proBNP, ET-1 and CGRP in the diagnosis of COPD complicated with pulmonary heart disease were 873.507 pg/mL, 117.625 ng/L and 33.228 pg/mL, respectively. In COPD with pulmonary heart disease group, the plasma levels of NT-proBNP and ET-1 in patients with different NYHA cardiac function grades were compared and showed in the order of grade Ⅱ<grade Ⅲ<grade Ⅳ, while CGRP level was opposite grade Ⅱ > grade Ⅲ > grade Ⅳ (P<0.05).Correlation analysis showed that plasma levels of NT-proBNP and ET-1 were positively correlated with NYHA cardiac function grade in COPD patients with pulmonary heart disease, while plasma level of CGRP was negatively correlated with NYHA cardiac function grade (P<0.05). 【Conclusion】Compared to simple COPD, levels of NT-proBNP and ET-1 in COPD patients with pulmonary heart disease were higher, while CGRP level was lower. The degree of cardiac function injury in COPD patients with pulmonary heart disease is positively correlated with the level of NT-proBNP and ET-1, and negatively correlated with the level of CGRP.

Key words： Pulmonary Disease, Chronic Obstructive/CO Pulmonary Heart Disease/CO Natriuretic Peptide, Brain /BL Endothelin-1/BL Calcitonin Gene-Related Peptide/BL Heart Function Tests

Received: 15 August 2022

PACS:

R563

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	REN Dan
	LEI Xin
	ZHANG Wei-qiang
	et al

Cite this article:

REN Dan,LEI Xin,ZHANG Wei-qiang, et al. Relationship of COPD Complicated with Pulmonary Heart Disease with Levels of NT-proBNP, ET-1 and CGRP in Elderly Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(7): 1025-1028.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2023.07.018 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2023/V40/I7/1025

[1] YANG Y L, XIANG Z J, YANG J H, et al. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease:a systematic review and meta-analysis[J].Eur Heart J,2020,41(46):4415-4422.
[2] SAKAO S. Chronic obstructive pulmonary disease and the early stage of cor pulmonale:A perspective in treatment with pulmonary arterial hypertension-approved drugs [J].Respir Investig,2019,57(4):325-329.
[3] FRILLE A, RULLMANN M, BECKER G A, et al. Increased pulmonary serotonin transporter in patients with chronic obstructive pulmonary disease who developed pulmonary hypertension[J].Eur J Nucl Med Mol Imaging,2021,48(4):1081-1092.
[4] 武铁力,秦迎新,卢冠男,等. 肺心病患者急性加重期及缓解期血浆内皮素-1与降钙素基因相关肽水平分析[J].中国地方病防治杂志,2017,32(8):898-899.
[5] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.慢性阻塞性肺疾病基层诊疗指南(2018年)[J].中华全科医师杂志,2018,17(11):856-870.
[6] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.慢性肺源性心脏病基层诊疗指南(2018年)[J].中华全科医师杂志,2018,17(12):959-965.
[7] HUNT S A, BAKER D W, CHIN M H, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:executive summary[J].J Heart Lung Transplant,2002,21(2):189-203.
[8] MANDOLI GE, SCIACCALUGA C, BANDERA F, et al. Cor pulmonale:the role of traditional and advanced echocardiography in the acute and chronic settings[J].Heart Fail Rev,2021,26(2):263-275.
[9] 李丽.慢性阻塞性肺疾病合并肺动脉高压病人血清CRP、cys C和ET-1水平变化及临床意义[J].中西医结合心脑血管病杂志,2021,19(6):1051-1053.
[10] 武俊慧,柴海强. 桉柠蒎肠溶软胶囊联合异丙托溴胺对慢性阻塞性肺疾病患者ET-1、corin、adiponectin水平的影响作用[J].湖南师范大学学报(医学版),2021,18(4):244-247.
[11] 蔡秋妍,陈璟.慢性肺源性心脏病急性加重期患者血浆PCT、NT-ProBNP水平的变化及临床意义[J].医学临床研究,2020,37(5):724-726.
[12] 赵智东,付会文,崔利锋,等.经鼻高流量加温湿化吸氧治疗对慢性阻塞性肺疾病合并肺源性心脏病的临床效果[J].检验医学与临床,2019,16(14):1989-1992.
[13] 赵明哲,陆晓亚.补肺化痰活血法联合西药治疗慢性阻塞性肺疾病合并肺动脉高压疗效及对血清NT-proBNP、ET-1、IL-17影响[J].现代中西医结合杂志,2017,26(19):2090-2093.
[14] 郑新远,王营,郑琳岐. 肺心病患者外周血periostin、ET-1、AVP水平及与血气分析的相关性[J].实验与检验医学,2021,39(6):1501-1504.
[15] 单洁龄. 宣肺祛瘀通络法对肺心病肺动脉高压患者血管内生长因子、内皮素和氧化应激水平的影响[J].中国中医急症,2018,27(6):1036-1038.
[16] 吕志刚,马树峰,刘丽娟,等. 室间隔缺损患儿血清BNP、cys C及CGRP水平与肺动脉高压的关系[J].分子诊断与治疗杂志,2022,14(3):475-478.